{"id":"herpes-zoster-vaccine-gsk1437173a","safety":{"commonSideEffects":[{"rate":"40–50%","effect":"Injection site pain"},{"rate":"30–40%","effect":"Injection site erythema"},{"rate":"20–30%","effect":"Injection site swelling"},{"rate":"30–40%","effect":"Myalgia"},{"rate":"20–30%","effect":"Fatigue"},{"rate":"20–30%","effect":"Headache"},{"rate":"5–15%","effect":"Fever"}]},"_chembl":null,"_dailymed":null,"mechanism":{"_ai_source":"claude-haiku-4.5","explanation":"GSK1437173A is a recombinant subunit vaccine containing VZV glycoprotein E (gE) combined with an AS01B adjuvant system to enhance immune response. The vaccine primes both cellular and humoral immunity against VZV, reducing the risk of herpes zoster reactivation and post-herpetic neuralgia in older adults and immunocompromised populations.","oneSentence":"This vaccine stimulates the immune system to recognize and attack varicella-zoster virus (VZV) to prevent herpes zoster (shingles) infection.","_ai_confidence":"high"},"_scrapedAt":"2026-03-28T01:15:13.435Z","_scrapedBy":"cloudflare-swarm","_wikipedia":null,"indications":{"approved":[{"name":"Prevention of herpes zoster (shingles) in adults aged 50 years and older"},{"name":"Prevention of herpes zoster in immunocompromised adults"}]},"trialDetails":[{"nctId":"NCT04006808","phase":"PHASE1, PHASE2","title":"A Study to Test GlaxoSmithKline's (GSK) Candidate Vaccine-GSK1437173A for Prevention of Shingles in Children With Kidney Transplant","status":"RECRUITING","sponsor":"GlaxoSmithKline","startDate":"2019-10-25","conditions":"Herpes Zoster","enrollment":184},{"nctId":"NCT02723773","phase":"PHASE3","title":"A Long-term Follow-up Study (ZOE-LTFU) of Two Studies 110390 (ZOSTER-006) and 113077 (ZOSTER-022) to Assess the Efficacy, Safety, and Immunogenicity Persistence of GSK Biologicals' Herpes Zoster Subunit (HZ/su) Vaccine and Assessment of 1 or 2 Additional Doses in Two Subgroups of Older Adults","status":"COMPLETED","sponsor":"GlaxoSmithKline","startDate":"2016-04-16","conditions":"Herpes Zoster, Herpes Zoster Vaccine","enrollment":7539},{"nctId":"NCT04091451","phase":"PHASE3","title":"Safety and Immunogenicity Study of GlaxoSmithKline's Herpes Zoster Subunit Vaccine (HZ/su) When Given on a Two-dose Schedule to Adults at Least 50 Years of Age (YOA) With a Prior Episode of Herpes Zoster","status":"COMPLETED","sponsor":"GlaxoSmithKline","startDate":"2019-09-17","conditions":"Herpes Zoster","enrollment":1430},{"nctId":"NCT04176939","phase":"PHASE3","title":"A Study to Test GlaxoSmithKline's (GSK) Herpes Zoster (HZ) Subunit Vaccine's Long-term Immune Response in Previously Vaccinated Kidney Transplant Adults and Then to Test if 2 Additional Doses of the Vaccine Are Safe and Able to Generate an Immune Response","status":"COMPLETED","sponsor":"GlaxoSmithKline","startDate":"2019-12-09","conditions":"Herpes Zoster","enrollment":68},{"nctId":"NCT04869982","phase":"PHASE4","title":"Efficacy, Immunogenicity and Safety Study of GSKs Recombinant Zoster Vaccine Shingrix (GSK1437173A) in Chinese Adults Aged ≥50 Years","status":"COMPLETED","sponsor":"GlaxoSmithKline","startDate":"2021-05-14","conditions":"Herpes Zoster","enrollment":6138},{"nctId":"NCT03894969","phase":"PHASE2","title":"Study to Assess the Immunogenicity and Safety of GSK's Investigational Vaccine (GSK3277511A) When Given to Healthy Smokers and Ex-smokers After Administration of Shingrix Vaccine","status":"COMPLETED","sponsor":"GlaxoSmithKline","startDate":"2019-04-23","conditions":"Respiratory Disorders","enrollment":541},{"nctId":"NCT02735915","phase":"PHASE3","title":"Study to Evaluate Immunogenicity and Safety of GSK Biologicals' Herpes Zoster Subunit (HZ/su) Vaccine at 9 and 10 Years After Vaccine Administration and Assessment of Re-vaccination With 2 Additional Doses at 10 Years After Initial Vaccination, in Healthy Subjects Aged 60 Years of Age(YOA) and Older","status":"COMPLETED","sponsor":"GlaxoSmithKline","startDate":"2016-04-11","conditions":"Herpes Zoster","enrollment":70},{"nctId":"NCT03439657","phase":"PHASE3","title":"Immunogenicity and Safety Study of GSK Biologicals' Herpes Zoster Vaccine GSK1437173A When Co-administered With Prevenar13 in Adults Aged 50 Years and Older","status":"COMPLETED","sponsor":"GlaxoSmithKline","startDate":"2018-04-12","conditions":"Herpes Zoster","enrollment":913},{"nctId":"NCT02075515","phase":"PHASE3","title":"Consistency, Immunogenicity and Safety Study of GlaxoSmithKline (GSK) Biologicals' Herpes Zoster (HZ) Vaccine GSK1437173A in Adults ≥ 50 Years of Age","status":"COMPLETED","sponsor":"GlaxoSmithKline","startDate":"2014-08-13","conditions":"Herpes Zoster, Herpes Zoster Vaccine","enrollment":651},{"nctId":"NCT02045836","phase":"PHASE3","title":"Study to Evaluate Immunogenicity and Safety Study of GSK Biologicals' Herpes Zoster (HZ) Vaccine GSK1437173A When Co-administered With Pneumovax 23™ in Adults Aged 50 Years and Older","status":"COMPLETED","sponsor":"GlaxoSmithKline","startDate":"2014-03-05","conditions":"Herpes Zoster, Herpes Zoster Vaccine","enrollment":865},{"nctId":"NCT01798056","phase":"PHASE3","title":"Immunogenicity and Safety Study of GlaxoSmithKline (GSK) Biologicals' Herpes Zoster (HZ/su) Vaccine in Adults With Solid Tumours Receiving Chemotherapy","status":"COMPLETED","sponsor":"GlaxoSmithKline","startDate":"2013-03-06","conditions":"Herpes Zoster, Herpes Zoster Vaccine","enrollment":237},{"nctId":"NCT02690207","phase":"PHASE3","title":"Cross-vaccination Study of GSK Biologicals' Herpes Zoster Subunit (HZ/su) Vaccine (GSK 1437173A) in Subjects Who Previously Received Placebo in ZOSTER-006 (NCT01165177) and ZOSTER-022 (NCT01165229) Studies.","status":"COMPLETED","sponsor":"GlaxoSmithKline","startDate":"2016-03-16","conditions":"Herpes Zoster","enrollment":8687},{"nctId":"NCT01165177","phase":"PHASE3","title":"Study to Evaluate Efficacy, Safety and Immunogenicity of GSK Biologicals' Herpes Zoster (HZ) Vaccine GSK1437173A in Adults Aged 50 Years and Older","status":"COMPLETED","sponsor":"GlaxoSmithKline","startDate":"2010-08-02","conditions":"Herpes Zoster","enrollment":16165},{"nctId":"NCT01165229","phase":"PHASE3","title":"Study to Evaluate Efficacy, Safety and Immunogenicity of GlaxoSmithKline (GSK) Biologicals' Herpes Zoster (HZ) Vaccine GSK1437173A in Adults Aged 70 Years and Older","status":"COMPLETED","sponsor":"GlaxoSmithKline","startDate":"2010-08-02","conditions":"Herpes Zoster, Herpes Zoster Vaccine","enrollment":14819},{"nctId":"NCT02979639","phase":"PHASE3","title":"Study to Evaluate the Impact of Reactogenicity on Quality of Life (QoL), After Administration of GlaxoSmithKline (GSK) Biologicals' Candidate Herpes Zoster Subunit (HZ/su) Vaccine (GSK1437173A) in Adults ≥ 50 Years of Age","status":"COMPLETED","sponsor":"GlaxoSmithKline","startDate":"2017-01-16","conditions":"Herpes Zoster","enrollment":404},{"nctId":"NCT00802464","phase":"PHASE2","title":"Immunogenicity and Safety Study of GSK Biologicals' Herpes Zoster Vaccine With Various Formulations in Adults >= 50 Years","status":"COMPLETED","sponsor":"GlaxoSmithKline","startDate":"2009-01-12","conditions":"Herpes Zoster","enrollment":410},{"nctId":"NCT00492648","phase":"PHASE2","title":"Month 30 & 42 Extension Studies of CRD-004 Primary Study","status":"COMPLETED","sponsor":"GlaxoSmithKline","startDate":"2007-06-25","conditions":"Herpes Zoster","enrollment":34},{"nctId":"NCT00434577","phase":"PHASE2","title":"Safety and Immunogenicity of the Zoster Vaccine GSK1437173A in Elderly Subjects","status":"COMPLETED","sponsor":"GlaxoSmithKline","startDate":"2007-02-14","conditions":"Herpes Zoster","enrollment":715},{"nctId":"NCT01777321","phase":"PHASE3","title":"Safety and Immunogenicity Study of GSK Biologicals' Herpes Zoster Subunit (HZ/su) Vaccine GSK1437173A When Administered Subcutaneously Intramuscularly in Adults Aged ≥50 Years","status":"COMPLETED","sponsor":"GlaxoSmithKline","startDate":"2013-06-17","conditions":"Herpes Zoster","enrollment":60},{"nctId":"NCT01751165","phase":"PHASE3","title":"Safety and Immunogenicity of Different Dosing Schedules of GlaxoSmithkline (GSK) Biologicals' Herpes Zoster (HZ) Vaccine in Adults 50 Years of Age or Older","status":"COMPLETED","sponsor":"GlaxoSmithKline","startDate":"2013-03-12","conditions":"Herpes Zoster","enrollment":354},{"nctId":"NCT01827839","phase":"PHASE3","title":"Immunogenicity and Safety of GlaxoSmithKline (GSK) Biologicals' Herpes Zoster Subunit (HZ/su) Vaccine GSK1437173A in Adults With a Prior Episode of Herpes Zoster","status":"COMPLETED","sponsor":"GlaxoSmithKline","startDate":"2013-06-10","conditions":"Herpes Zoster","enrollment":96},{"nctId":"NCT02581410","phase":"PHASE3","title":"Immunogenicity and Safety Study of GlaxoSmithKline (GSK) Biologicals' Herpes Zoster Subunit (HZ/su) Vaccine (GSK1437173A) in Adults ≥ 65 Years of Age With and Without Zostavax® Vaccination at Least 5 Years Earlier","status":"COMPLETED","sponsor":"GlaxoSmithKline","startDate":"2015-12-15","conditions":"Herpes Zoster","enrollment":430},{"nctId":"NCT02058589","phase":"PHASE3","title":"Immunogenicity and Safety of GlaxoSmithKline (GSK) Biologicals' Herpes Zoster Subunit (HZ/su) Vaccine in Adults 18 Years of Age or Older With Renal Transplant","status":"COMPLETED","sponsor":"GlaxoSmithKline","startDate":"2014-03-20","conditions":"Herpes Zoster","enrollment":265},{"nctId":"NCT01767467","phase":"PHASE3","title":"Study to Assess the Safety and Immunogenicity of GlaxoSmithKline (GSK) Biologicals' Herpes Zoster Subunit (HZ/su) Vaccine in Adults Aged 18 Years and Older With Blood Cancers","status":"COMPLETED","sponsor":"GlaxoSmithKline","startDate":"2013-03-01","conditions":"Herpes Zoster","enrollment":568},{"nctId":"NCT01954251","phase":"PHASE3","title":"Study to Evaluate the Immunogenicity and Safety of GlaxoSmithKline (GSK) Biologicals' Herpes Zoster Vaccine GSK1437173A When Co-administered With GSK Biologicals' Seasonal Influenza Vaccine GSK2321138A in Adults Aged 50 Years and Older","status":"COMPLETED","sponsor":"GlaxoSmithKline","startDate":"2013-10-03","conditions":"Herpes Zoster","enrollment":829},{"nctId":"NCT01165203","phase":"PHASE2","title":"Study to Evaluate GSK Biologicals' Herpes Zoster Vaccine GSK1437173A in Human Immunodeficiency Virus (HIV)-Infected Subjects","status":"COMPLETED","sponsor":"GlaxoSmithKline","startDate":"2010-09-30","conditions":"Herpes Zoster","enrollment":123},{"nctId":"NCT02052596","phase":"PHASE3","title":"Study to Assess the Immunogenicity and Safety of GlaxoSmithKline (GSK) Biologicals' Herpes Zoster Subunit (HZ/su) Vaccine (GSK1437173A) When Co-administered With GSK Biologicals' Diphtheria, Tetanus and Pertussis Vaccine (Boostrix®) in Adults Aged 50 Years and Older","status":"COMPLETED","sponsor":"GlaxoSmithKline","startDate":"2014-02-07","conditions":"Herpes Zoster","enrollment":935},{"nctId":"NCT01086449","phase":"PHASE1","title":"Safety and Immunogenicity of GSK Biologicals' Herpes Zoster Vaccine 1437173A in Healthy Ethnic Japanese Adults","status":"COMPLETED","sponsor":"GlaxoSmithKline","startDate":"2010-03-04","conditions":"Herpes Zoster","enrollment":20},{"nctId":"NCT01610414","phase":"PHASE3","title":"Study to Evaluate Efficacy, Safety, and Immunogenicity of GlaxoSmithKline (GSK) Biologicals' Herpes Zoster Vaccine GSK1437173A","status":"COMPLETED","sponsor":"GlaxoSmithKline","startDate":"2012-07-13","conditions":"Herpes Zoster","enrollment":1877},{"nctId":"NCT00920218","phase":"PHASE2","title":"Safety & Immunogenicity of GlaxoSmithKline Biologicals' Herpes Zoster Vaccine 1437173A","status":"COMPLETED","sponsor":"GlaxoSmithKline","startDate":"2009-07-14","conditions":"Herpes Zoster","enrollment":121},{"nctId":"NCT01295320","phase":"PHASE2","title":"Study of Long Term Immune Responses and Safety of the GSK Herpes Zoster Vaccine in Healthy Subjects","status":"COMPLETED","sponsor":"GlaxoSmithKline","startDate":"2011-02-28","conditions":"Herpes Zoster","enrollment":129}],"_emaApprovals":[],"_faersSignals":[],"_approvalHistory":[],"publicationCount":1,"rwe":[],"genericFilers":[],"relatedDrugs":[],"labelChanges":[],"biosimilarFilings":[],"pricing":[],"formularyStatus":[],"manufacturing":[],"companionDiagnostics":[],"competitors":[],"timeline":[],"patents":[],"ownershipHistory":[],"trials":[],"biosimilars":[],"latestUpdates":[],"references":[],"tags":[],"ecosystem":[],"genericManufacturerList":[],"offLabel":[],"developmentCodes":[],"aliases":["HZ/su vaccine","gE/AS01E","gE/AS01B","HZ/su"],"phase":"phase_3","status":"active","brandName":"Herpes Zoster vaccine GSK1437173A","genericName":"Herpes Zoster vaccine GSK1437173A","companyName":"GlaxoSmithKline","companyId":"gsk","modality":"Biologic","firstApprovalDate":"","aiSummary":"This vaccine stimulates the immune system to recognize and attack varicella-zoster virus (VZV) to prevent herpes zoster (shingles) infection. Used for Prevention of herpes zoster (shingles) in adults aged 50 years and older, Prevention of herpes zoster in immunocompromised adults.","enrichmentLevel":3,"visitCount":1,"trialStats":{"total":2,"withResults":2},"verificationStatus":"verified","dataCompleteness":{"mechanism":true,"indications":true,"safety":true,"trials":true,"score":4}}